Jane Street’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-29,404
Closed -$172K 10469
2022
Q4
$172K Buy
29,404
+18,992
+182% +$99.9K ﹤0.01% 7776
2022
Q3
$70K Buy
+10,412
New +$63.1K ﹤0.01% 8802
2022
Q2
Sell
-16,627
Closed -$56K 11357
2022
Q1
$56K Buy
+16,627
New +$52.7K ﹤0.01% 9656
2021
Q3
Sell
-26,404
Closed -$111K 11055
2021
Q2
$111K Buy
+26,404
New +$112K ﹤0.01% 9213
2020
Q4
Sell
-16,647
Closed -$163K 8332
2020
Q3
$163K Buy
+16,647
New +$164K ﹤0.01% 6549
2018
Q1
Sell
-17,421
Closed -$451K 5602
2017
Q4
$451K Buy
+17,421
New +$351K ﹤0.01% 3306
2015
Q2
Sell
-20,330
Closed -$308K 4173
2015
Q1
$308K Buy
+20,330
New +$284K ﹤0.01% 2496

Jane Street's CNCE Position: Q1 2023 in Review

Jane Street sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 29,404 shares — an estimated $172K sold.

Jane Street first reported a position in CNCE in Q1 2015 and held it in 7 quarters. The position peaked at $451K in Q4 2017. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

  • Jane Street reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Jane Street sold 29,404 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $172K.
  • Jane Street first reported a position in Concert Pharmaceuticals, Inc. in Q1 2015 and held it in 7 quarters.
  • Jane Street's Concert Pharmaceuticals, Inc. position peaked at $451K in Q4 2017.
  • 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Jane Street's 13F filing for Q1 2023, filed 16 May 2023.